Bladder Cancer Coverage from Every Angle

Jonathan E. Rosenberg, MD, on Clinical Implications of New Findings on Durvalumab Plus Olaparib for Stage IV Urothelial Cancer

Posted: Tuesday, March 8, 2022

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II results from the BAYOU trial as well as the potential benefits of combining a checkpoint inhibitor and a PARP inhibitor in the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.